Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Dél-KoreaFázis nélkül

Continuous Glucose Monitoring and Dietary Self-Management in Adults in Namwon

A legfontosabb adatok

Ki végzi
Ji-Yeob Choi
Hol
Namwon (Dél-Korea)Mind a 4 helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
860 fő, tervezett
Kezdés
2026. nov. 2.
Várható befejezés
2028. szept.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Continuous Glucose Monitoring With Application-Based Biofeedback
  • Common Standardized Education and Behavioral Goal Setting
  • Common Digital Health Program and Basic Health Counseling
A regiszteradat frissítve
2026. október 22.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat 40 éves vagy idősebb, a koreai Namwonban élő felnőtteket keres, akiknek magas az éhgyomri vércukra, vagy igazolt 2-es típusú cukorbetegségük van. Azt vizsgálja, hogy egy glükózszenzor segít-e az egészséges étkezési szokásokban.

Életkor
40 éves vagy idősebb
Nem
Nemtől függetlenül bárki részt vehet.
A betegség stádiuma
Igazolt 2-es típusú cukorbetegség vagy annak kezelése, illetve 100 és 125 mg/dL közötti (vagy legalább 126 mg/dL) éhgyomri vércukor diagnózis vagy kezelés nélkül.
Korábbi kezelés
Korábban nem használhatott folyamatos glükózmérő (CGM) szenzort. Nem vehetett részt a namwoni közegészségügyi központ munkatársi pilot programjában.
Biomarker vagy leletérték
Az első szűrővizsgálat előtti két éven belüli éhgyomri vércukor-eredmény, kivéve ha a 2-es típusú cukorbetegség diagnózisa vagy kezelése igazolt.

A részvétel fő kizáró okai

  • 1-es típusú cukorbetegség
  • Bármilyen korábbi vagy jelenlegi CGM szenzorhasználat
  • Terhesség
  • Súlyos bőrbetegség a szenzor helyén vagy súlyos ragasztóallergia
  • Közelmúltbeli akut szív- és érrendszeri esemény, súlyos fertőzés vagy aktív daganatellenes kezelés

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • Resident of Namwon, Republic of Korea, aged 40 years or older
  • Able to understand the study, express a choice, and provide voluntary written informed consent
  • Able to participate in questionnaires, health-record review, dietary assessment, counseling, and basic measurements, with research-team assistance for smartphone or application use when needed
  • At least one of the following glycemic-risk criteria: documented type 2 diabetes diagnosis or treatment with glucose-lowering medication or insulin; no documented diagnosis or treatment with the most recent fasting glucose at least 126 mg/dL; or no documented diagnosis or treatment with the most recent fasting glucose from 100 through 125 mg/dL
  • Eligibility is verified at the first screening visit. Randomization preferably occurs that day but may occur later, without a separate maximum interval, after required consent and pre-allocation assessments. Before allocation, willingness to participate, treatment, safety status, and sensor-use changes are rechecked. The actual randomization date is Day 0. If it differs from screening, the four dietary self-management items are repeated before allocation; other baseline measures remain those from the first screening visit. Participants without a qualifying fasting glucose result or objective type 2 diabetes diagnosis or treatment documentation at that visit are not randomized. For fasting-glucose-based eligibility, the result must be from within two years before the first screening visit. The most recent available national health-screening result is used, unless a more recent medical-facility result explicitly identified as fasting glucose is provided. Existing diagnosis or treatment must be supported by objective documentation such as a prescription record, medication package or medication itself, or a medical certificate; self-report alone is insufficient. Documented type 2 diabetes diagnosis or treatment permits eligibility without an available fasting glucose result. Relevant partial copies or on-site review of application screens or paper records may be used; submission of the whole health-record file is not required
  • Provides additional written consent for continuous glucose monitoring (CGM), application linkage, data collection, and week 6 and week 12 assessments
  • Provides the separate consents required for transfer of PASTA personal and health data and provision of consent-confirmation information to Kakao Healthcare
  • Investigator judges that CGM can be used safely and follow-up procedures can be completed with assistance when needed

Ki nem vehet részt

  • Severe anxiety about sensor readings or concern that CGM use could compromise safe medication or dietary management
  • Any previous or current CGM sensor use, regardless of product, purpose, or duration, or planned non-study CGM use before the week 6 assessment. Clinically necessary CGM use will not be stopped for study participation
  • Previous participation in the Namwon public health center employee pilot program. Receiving information or making a reservation alone does not constitute prior participation; Welfare-center participants who have not used a sensor may enter the main study within the 860-participant target only after approval of the amendment, new informed consent, and confirmation of all eligibility criteria. Previously collected welfare-center data are handled only within the scope permitted by ethics review; public health center pilot data are excluded from the main study analysis
  • Acute illness, severe symptoms, or another condition that makes study procedures unsafe in the investigator's judgment
  • Severe skin disease at the sensor site, severe adhesive allergy, or a history of serious contact dermatitis
  • Recent acute cardiovascular event, severe infection, active anticancer treatment, or another condition making participation clinically inappropriate
  • Type 1 diabetes. Insulin treatment alone does not establish type 1 diabetes
  • Pregnancy or a need for a separate pregnancy-related glucose-management pathway
  • Unable to understand study-related information or express a choice, or unable to provide valid consent

Helyszínek itt: Dél-Korea

  • Namwon City HallNamwon, Dél-KoreaContact: Ji-Yeob Choi, PhDToborzás még nem indult
  • Namwon Medical CenterNamwon, Dél-KoreaContact: Ji-Yeob Choi, PhDToborzás még nem indult
  • Namwon Public Health CenterNamwon, Dél-KoreaContact: Ji-Yeob Choi, PhDToborzás még nem indult
  • Namwon Senior Welfare CenterNamwon, Dél-KoreaContact: Ji-Yeob Choi, PhDToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study will test whether adding a continuous glucose monitoring (CGM) device, which shows personal glucose patterns, improves dietary self-management over the first 6 weeks. Both groups receive the same digital health program, standardized education, and support for setting behavioral goals. It will include 860 residents of Namwon, Republic of Korea, aged 40 years or older who have elevated fasting glucose or documented type 2 diabetes diagnosis or treatment.

A teljes eredeti leírásKevesebb

After screening, participants will be assigned by chance to one of two groups of 430. Assignment is preferably on the first screening visit but may occur later. The actual assignment date is Day 0. The device group will use one CGM sensor for approximately 10 days after assignment. The wait-list control group will receive the same education and behavioral goal-setting support during the first 6 weeks, without a CGM device. Researchers will compare dietary self-management scores at week 6, before the control group receives a sensor.

After the week 6 assessment and data lock, the control group will also be offered a sensor so that all eligible randomized participants have an opportunity to use the device. This later offer is not the main intervention comparison. Week 12 assessments provide exploratory follow-up after both groups have been offered a device. Researchers will also assess application use, body weight, waist circumference, blood pressure, and safety. The research team will not change medicines based on sensor readings, and usual medical care will continue.

A vizsgálat 2 csoportja

  • CGM Biofeedback Device Plus Common ProgramA vizsgált kezelés

    Participants receive one Dexcom G7 continuous glucose monitoring (CGM) sensor on the actual randomization date (Day 0) or within 10 business days and wear it for approximately 10 days. The device provides personal glucose biofeedback through PASTA during the first 6-week comparison period. Both groups receive the same digital health program, standardized education, and behavioral goal-setting support; these are common background care. Sensor placement, connection, and safety instructions accompany actual device use. The primary assessment is at week 6 (Days 35-49), before the control group is offered a device. Week 12 (Days 77-91) is exploratory follow-up. The dietary baseline is collected before allocation on Day 0; other baseline measures are from the first screening visit. Same-day placement is optional.

    Kezelés: Continuous Glucose Monitoring With Application-Based Biofeedback, Common Standardized Education and Behavioral Goal Setting és Common Digital Health Program and Basic Health Counseling

  • Common Program With Wait-List CGMMár használt kezelés, összehasonlításként

    During the first 6 weeks, participants receive the same digital health program, standardized education, and behavioral goal-setting support as the device group, without a CGM device. Education and goal setting are not delayed. The primary assessment is at week 6 (Days 35-49). After that assessment and data lock, participants are offered one Dexcom G7 sensor on that day or within 7 business days, for approximately 10 days, so that all eligible participants have an opportunity to use it. Placement, connection, and device safety instructions accompany this later offer. Same-day placement is optional. Week 12 (Days 77-91) is exploratory follow-up, not a second device-versus-no-device comparison. Day 0 is actual randomization; the dietary baseline is collected before allocation that day and other baseline measures are from the first screening visit.

    Kezelés: Continuous Glucose Monitoring With Application-Based Biofeedback, Common Standardized Education and Behavioral Goal Setting és Common Digital Health Program and Basic Health Counseling

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Community-Based Digital Health Management Intervention Study in Namwon
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
A regiszteradat frissítve
2026. október 22.